Darin K. Edwards

8.4k total citations · 2 hit papers
23 papers, 1.0k citations indexed

About

Darin K. Edwards is a scholar working on Infectious Diseases, Animal Science and Zoology and Immunology. According to data from OpenAlex, Darin K. Edwards has authored 23 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Infectious Diseases, 10 papers in Animal Science and Zoology and 9 papers in Immunology. Recurrent topics in Darin K. Edwards's work include SARS-CoV-2 and COVID-19 Research (22 papers), Viral gastroenteritis research and epidemiology (10 papers) and Animal Virus Infections Studies (10 papers). Darin K. Edwards is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (22 papers), Viral gastroenteritis research and epidemiology (10 papers) and Animal Virus Infections Studies (10 papers). Darin K. Edwards collaborates with scholars based in United States, United Kingdom and Canada. Darin K. Edwards's co-authors include Andrea Carfı́, Dan H. Barouch, Makda S. Gebre, Lisa H. Tostanoski, Luis A. Brito, Rituparna Das, Jacqueline M. Miller, Bethany Girard, David C. Montefiori and Ying Chang and has published in prestigious journals such as Nature, New England Journal of Medicine and Cell.

In The Last Decade

Darin K. Edwards

22 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Bivalent Omicron-Containing Booster Vaccine against Covid-19

2022 346 citations Spyros Chalkias, Charles Harper et al. profile →
Novel approaches for vaccine development

2021 220 citations Makda S. Gebre, Luis A. Brito et al. Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Darin K. Edwards United States	11	781	315	208	177	140	23	1.0k
Tania Garron United States	12	1.2k 1.5×	221 0.7×	220 1.1×	285 1.6×	91 0.7×	18	1.4k
Frauke Muecksch United States	12	1.3k 1.7×	322 1.0×	198 1.0×	151 0.9×	145 1.0×	20	1.5k
Wan Rong Sia Singapore	8	841 1.1×	125 0.4×	263 1.3×	151 0.9×	73 0.5×	13	1.1k
Alison Tarke United States	9	813 1.0×	320 1.0×	320 1.5×	83 0.5×	82 0.6×	17	1.0k
Kim E. Schmidt Germany	5	417 0.5×	287 0.9×	186 0.9×	86 0.5×	78 0.6×	6	678
Nathaniel I. Bloom United States	6	732 0.9×	254 0.8×	271 1.3×	78 0.4×	80 0.6×	6	895
Wen Shi Lee Australia	15	807 1.0×	223 0.7×	459 2.2×	74 0.4×	68 0.5×	39	1.2k
Henning Gruell Germany	17	782 1.0×	234 0.7×	317 1.5×	69 0.4×	47 0.3×	52	1.2k
Hyon‐Xhi Tan Australia	17	611 0.8×	253 0.8×	476 2.3×	55 0.3×	56 0.4×	35	1.1k
Sebastian Ols Sweden	12	374 0.5×	366 1.2×	399 1.9×	75 0.4×	28 0.2×	20	867

Countries citing papers authored by Darin K. Edwards

Since Specialization

Citations

This map shows the geographic impact of Darin K. Edwards's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Darin K. Edwards with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Darin K. Edwards more than expected).

Fields of papers citing papers by Darin K. Edwards

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Darin K. Edwards. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Darin K. Edwards. The network helps show where Darin K. Edwards may publish in the future.

Co-authorship network of co-authors of Darin K. Edwards

This figure shows the co-authorship network connecting the top 25 collaborators of Darin K. Edwards. A scholar is included among the top collaborators of Darin K. Edwards based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Darin K. Edwards. Darin K. Edwards is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bangaru, Sandhya, Abigail M. Jackson, Jeffrey Copps, et al.. (2025). Structural serology of polyclonal antibody responses to mRNA-1273 and NVX-CoV2373 COVID-19 vaccines. Cell Reports. 44(7). 115986–115986.

Chalkias, Spyros, Rahnuma Wahid, Darin K. Edwards, et al.. (2025). Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): results from a phase 3, randomised, observer-blind, active-controlled trial. The Lancet Infectious Diseases. 25(11). 1230–1242. 6 indexed citations

Lee, Diana, Arshan Nasir, Sayda M. Elbashir, et al.. (2025). mRNA-1273 vaccines adapted to JN.1 or KP.2 elicit cross-neutralizing responses against the JN.1 sublineages of SARS-CoV-2 in mice. Vaccine. 54. 126961–126961. 3 indexed citations

Chalkias, Spyros, Adebayo Akinsola, Gary Berman, et al.. (2025). Safety and Immunogenicity of SARS-CoV-2 Spike Receptor-Binding Domain and N-Terminal Domain mRNA Vaccine. The Journal of Infectious Diseases. 231(4). e754–e763. 7 indexed citations

Figueroa, Amparo L., Bethany Girard, Darin K. Edwards, et al.. (2025). Immunogenicity of JN.1- and KP.2-Encoding mRNA COVID-19 Vaccines Against JN.1 Subvariants in Adult Participants. Open Forum Infectious Diseases. 12(12). ofaf705–ofaf705. 1 indexed citations

Ying, Baoling, Chieh-Yu Liang, Pritesh Desai, et al.. (2024). Ipsilateral or contralateral boosting of mice with mRNA vaccines confers equivalent immunity and protection against a SARS-CoV-2 Omicron strain. Journal of Virology. 98(9). e0057424–e0057424. 3 indexed citations

Iqbal, Shehzad, Andrew M. Rosen, Darin K. Edwards, et al.. (2024). Opportunities and challenges to implementing mRNA-based vaccines and medicines: lessons from COVID-19. Frontiers in Public Health. 12. 1429265–1429265. 9 indexed citations

Liang, Chieh-Yu, Saravanan Raju, Zhuoming Liu, et al.. (2024). Imprinting of serum neutralizing antibodies by Wuhan-1 mRNA vaccines. Nature. 630(8018). 950–960. 25 indexed citations

Chalkias, Spyros, Nichole McGhee, Brandon Essink, et al.. (2024). Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB–Containing Vaccines. The Journal of Infectious Diseases. 230(2). e279–e286. 36 indexed citations

10.

Schramm, Chaim A., Noemia S. Lima, Kristin L. Boswell, et al.. (2023). Interaction dynamics between innate and adaptive immune cells responding to SARS-CoV-2 vaccination in non-human primates. Nature Communications. 14(1). 7961–7961. 5 indexed citations

11.

Meyer, Michelle, Chiaowen Joyce Hsiao, Albert B. Jeon, et al.. (2023). Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection. Science Advances. 9(38). eadh1655–eadh1655. 43 indexed citations

12.

Mackin, Samantha, Pritesh Desai, Bradley Whitener, et al.. (2023). Fc-γR-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2. Nature Microbiology. 8(4). 569–580. 47 indexed citations

13.

Chalkias, Spyros, Charles Harper, Keith Vrbicky, et al.. (2023). Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19. Nature Communications. 14(1). 5125–5125. 11 indexed citations

14.

Ying, Baoling, Bradley Whitener, Laura A. VanBlargan, et al.. (2022). Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains. Science Translational Medicine. 14(630). eabm3302–eabm3302. 36 indexed citations

15.

Chu, Laurence, Keith Vrbicky, David C. Montefiori, et al.. (2022). Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial. Nature Medicine. 28(5). 1042–1049. 56 indexed citations

16.

Darling, Tamarand L., Baoling Ying, Bradley Whitener, et al.. (2022). mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2. Med. 3(5). 309–324.e6. 6 indexed citations

17.

Edwards, Darin K. & Andrea Carfı́. (2022). Messenger ribonucleic acid vaccines against infectious diseases: current concepts and future prospects. Current Opinion in Immunology. 77. 102214–102214. 9 indexed citations

18.

Henry, Carole, LingZhi Ma, Nicholas J. Amato, et al.. (2022). Altering the mRNA-1273 dosing interval impacts the kinetics, quality, and magnitude of immune responses in mice. Frontiers in Immunology. 13. 948335–948335. 7 indexed citations

19.

Chalkias, Spyros, Frank Eder, Brandon Essink, et al.. (2022). Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial. Nature Medicine. 28(11). 2388–2397. 70 indexed citations

20.

Gebre, Makda S., Luis A. Brito, Lisa H. Tostanoski, et al.. (2021). Novel approaches for vaccine development. Cell. 184(6). 1589–1603. 220 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact